TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Researchers from Virginia Commonwealth University detail findings in gene therapy
June 23rd, 2009
"Immunocompromised patients are at risk for invasive molds and resistant fungal infections for which amphotericin B may be the only feasible treatment. Nephrogenic diabetes insipidus (Di) and renal tubular acidosis are known adverse effects of conventional amphotericin 13 however, nephrogenic DI has been uncommonly associated with liposomal amphotericin B formulations," investigators in the United States report. "We describe an 18-year-old woman with aplastic anemia who developed invasive aspergillosis. She began treatment with high-close (10 mg/kg/day) liposomal amphotericin B at horned however, her condition worsened, and she was hospitalized. Therapy with liposomal...
Source: TB & Outbreaks Week (2009-06-23)
|
